当前位置:首页 - 行情中心 - 恩威医药(301331) - 财务分析 - 现金流量表

恩威医药

(301331)

  

流通市值:33.58亿  总市值:33.65亿
流通股本:1.03亿   总股本:1.03亿

现金流量表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金617,234,284.42424,612,821.23199,425,776.38745,712,774.63
  收到其他与经营活动有关的现金706,090.58597,312.85476,026.613,975,507
  经营活动现金流入小计617,940,375425,210,134.08199,901,802.99749,688,281.63
  购买商品、接受劳务支付的现金212,806,912.38138,969,340.0568,744,924.24275,137,935.42
  支付给职工以及为职工支付的现金140,699,507.0695,976,777.6550,309,344.03196,456,475.92
  支付的各项税费56,987,675.735,206,945.9218,649,415.2480,865,441.4
  支付其他与经营活动有关的现金131,244,244.8579,874,909.6437,519,993.99118,308,709.06
  经营活动现金流出小计541,738,339.99350,027,973.26175,223,677.5670,768,561.8
  经营活动产生的现金流量净额76,202,035.0175,182,160.8224,678,125.4978,919,719.83
二、投资活动产生的现金流量:
  收回投资收到的现金818,200818,200--
  取得投资收益收到的现金3,100,620.052,124,925.621,083,803.963,930,500.34
  处置固定资产、无形资产和其他长期资产收回的现金净额41,10041,100-344,080
  收到的其他与投资活动有关的现金1,263,334,527.01862,466,589.53421,395,523.22953,442,976.79
  投资活动现金流入小计1,267,294,447.06865,450,815.15422,479,327.18957,717,557.13
  购建固定资产、无形资产和其他长期资产支付的现金46,626,693.6634,208,178.0717,453,732.7350,232,429.94
  投资支付的现金75,000---
  支付其他与投资活动有关的现金1,300,010,100870,010,100425,000,0001,018,102,500
  投资活动现金流出小计1,346,711,793.66904,218,278.07442,453,732.731,068,334,929.94
  投资活动产生的现金流量净额-79,417,346.6-38,767,462.92-19,974,405.55-110,617,372.81
三、筹资活动产生的现金流量:
  吸收投资收到的现金---18,363,611.13
  取得借款收到的现金---241,800,000
  筹资活动现金流入平衡项目---0
  筹资活动现金流入小计---260,163,611.13
  偿还债务支付的现金5,970,397.045,716,002.98-46,800,000
  分配股利、利润或偿付利息支付的现金20,471,731.0919,864,786.65828,75056,957,196.04
  支付其他与筹资活动有关的现金---71,301,845.07
  筹资活动现金流出小计26,442,128.1325,580,789.63828,750175,059,041.11
  筹资活动产生的现金流量净额-26,442,128.13-25,580,789.63-828,75085,104,570.02
四、汇率变动对现金及现金等价物的影响-70.8-25.42-8.6990.3
五、现金及现金等价物净增加额-29,657,510.5210,833,882.853,874,961.2553,407,007.34
  加:期初现金及现金等价物余额289,223,789.55289,223,789.55289,223,789.55235,816,782.21
  期末现金及现金等价物余额259,566,279.03300,057,672.4293,098,750.8289,223,789.55
补充资料:
  净利润-38,344,181.25-37,497,544.35
  资产减值准备--669,701.68-5,384,313.82
  固定资产和投资性房地产折旧-14,448,199.75-28,737,915.69
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-14,448,199.75-28,737,915.69
  无形资产摊销-8,235,187.55-16,476,460.65
  长期待摊费用摊销-2,196,076.4-6,232,115.83
  处置固定资产、无形资产和其他长期资产的损失-263,274.66-263,488.07
  固定资产报废损失-108,565.71-53,861.47
  财务费用-249,893.3--1,589,668.74
  投资损失--2,818,800.74--3,494,421.27
  递延所得税--1,791,185.04--1,804,005.3
  其中:递延所得税资产减少--711,245.97--1,593,051.91
    递延所得税负债增加--1,079,939.07--210,953.39
  存货的减少-4,609,887.6--12,062,423.34
  经营性应收项目的减少-11,822,549.46--36,426,964.25
  经营性应付项目的增加--5,503,881.4-12,961,182.47
  其他-5,057,516.38-25,425,884.76
  现金的期末余额-300,057,672.4-289,223,789.55
  减:现金的期初余额-289,223,789.55-235,816,782.21
  现金及现金等价物的净增加额-10,833,882.85-53,407,007.34
公告日期2025-10-302025-08-262025-04-212025-04-21
审计意见(境内)标准无保留意见
TOP↑